Roth Capital upgraded Coherus Biosciences (CHRS) to Buy from Neutral.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Oncology’s Earnings Call Highlights Growth and Challenges
- Coherus Biosciences: Buy Rating Affirmed Amid Strong Sales Alignment and Promising Pipeline Developments
- Coherus Biosciences: Promising Growth and Strategic Positioning Justify Buy Rating
- Coherus Oncology Reports Strong Q2 2025 Growth
- Coherus Biosciences reports Q2 EPS (39c), consensus (27c)